ATLASGAL - evolutionary trends in high-mass star formation

ATLASGAL is an 870-μm dust survey of 420 deg2 the inner Galactic plane and has been used to identify ∼10 000 dense molecular clumps. Dedicated follow-up observations and complementary surveys are used to characterize the physical properties of these clumps, map their Galactic distribution, and investigate the evolutionary sequence for high-mass star formation. The analysis of the ATLASGAL data is ongoing: We present an up-to-date version of the catalogue. We have classified 5007 clumps into four evolutionary stages (quiescent, protostellar, young stellar objects and H ii regions) and find similar numbers of clumps in each stage, suggesting a similar lifetime. The luminosity-to-mass (Lbol/Mfwhm) ratio curve shows a smooth distribution with no significant kinks or discontinuities when compared to the mean values for evolutionary stages indicating that the star formation process is continuous and that the observational stages do not represent fundamentally different stages or changes in the physical mechanisms involved. We compare the evolutionary sample with other star formation tracers (methanol and water masers, extended green objects and molecular outflows) and find that the association rates with these increases as a function of evolutionary stage, confirming that our classification is reliable. This also reveals a high association rate between quiescent sources and molecular outflows, revealing that outflows are the earliest indication that star formation has begun and that star formation is already ongoing in many of the clumps that are dark even at 70 μm

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Abstract BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)